Concordance in assessments between investigators and blinded independent central review (BICR) in hematology oncology clinical trials: a meta-analysis
Investigator and BICR assessments demonstrated substantial concordance in hematology trials. The common applications of BICR in registration trials provide minimal added value for primary endpoint validation in this setting. We recommend prioritizing investigator training and standardized criteria to optimize resource allocation.
Authors
- Bujian Cui (ORCID: https://orcid.org/0000-0002-5809-9344)
- Yang Dang (ORCID: https://orcid.org/0000-0001-8282-6321)
- Xiaoyu Luo (ORCID: https://orcid.org/0000-0002-8202-2822)
- Hui Zhang (ORCID: https://orcid.org/0000-0001-6825-5649)
- Xiaoyu Tang (ORCID: https://orcid.org/0000-0002-7236-3201)
- Yi Kang
- Seong S. Han
Institutions
- Boston University (US)
- University of Liverpool (GB)
- Pfizer (United States) (US)
- Pfizer (China) (CN)
- Xi’an Jiaotong-Liverpool University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf375
- Primary Topic
- Meta-analysis and systematic reviews
- Type
- article
- Field-Weighted Citation Impact
- 0.00